Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An autosomal dominant disorder caused by specific pathogenic variants in the APC gene promoter, characterized by proximal gastric polyposis and an increased risk of gastric adenocarcinoma.
Features include always present findings: Fundic gland polyposis; and common findings: Gastric adenocarcinoma and Abdominal pain. 4 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Digestive system | 1 | Abdominal pain |
APC-associated polyposis conditions include classic familial adenomatous polyposis (FAP), attenuated FAP, and gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS). FAP In individuals with classic FAP, colorectal adenomatous polyps begin to appear in the second and third decade; the average age of polyp diagnosis is 16 years (range 7-36 years) . By age 35 years, 95% of individuals with FAP have polyps. Once they appear, the polyps rapidly increase in number; when colonic expression is fully developed, hundreds to thousands of colonic adenomatous polyps are typically observed. Without colectomy, colorectal cancer (CRC) is essentially inevitable. The average age of CRC diagnosis in untreated individuals is 39 years (range 34-43 years); 7% of untreated individuals with FAP develop CRC by age 21 years, 87% by 45 years, and 93% by 50 years. Although rare, asymptomatic individuals in their 50s have been reported. Inter- and intrafamilial phenotypic variability are common . Attenuated FAP is characterized by fewer colonic polyps (average of 30 polyps) than classic FAP but a significant risk for CRC. According to the international collaborative study by , attenuated FAP was clinically defined as individuals with ≤100 colorectal adenomatous polyps at age ≥25 years. Polyps tend to occur more proximally in the colon than in classic FAP. The average age of CRC diagnosis in individuals with attenuated FAP is 50 to 55 years – ten to 15 years later than in classic FAP, but earlier than in those with sporadically occurring CRC . The cumulative risk for CRC by age 80 years in attenuated FAP is estimated at 70% . Other Features Variably Present in FAP Table 2. Lifetime Risk for Extracolonic Cancer in Familial Adenomatous Polyposis
Site | Type of Cancer | Lifetime Risk for Cancer |
|---|---|---|
Small bowel: duodenum (most often periampullary region) | Adenocarcinoma, carcinoma | 4%-12% |
Small bowel: distal to the duodenum | Carcinoma | Rare |
Pancreas | Adenocarcinoma | ~1% |
Thyroid | Papillary thyroid carcinoma | 1%-12% |
CNS | Usually medulloblastoma | ~1% |
Liver | Hepatoblastoma | 1.6% |
Bile ducts | Adenocarcinoma | Low, but |
Stomach | Adenocarcinoma | 1.3% in Western cultures since 2016 Small-bowel polyps and cancer. Adenomatous polyps of the duodenum, observed in 50%-90% of individuals with FAP, are commonly found in the second and third portions of the duodenum and to a variable degree in the jejunum or ileum . |
Source: GeneReviews — "APC-Associated Polyposis Conditions"
APC encodes APC regulator of Wnt signaling pathway (2,843 aa). Tumor suppressor. Promotes rapid degradation of CTNNB1 and participates in Wnt signaling as a negative regulator. APC activity is correlated with its phosphorylation state. Highest expression in Brain Frontal Cortex BA9 (37.0 TPM) and Brain Cortex (36.9 TPM).
Gastric adenocarcinoma and proximal polyposis of the stomach is caused by mutations in the APC gene on chromosome 5.
APC is classified as a druggable target (Clinically Actionable category) with score 2.4.
Although inter- and intrafamilial variability is common in FAP, there are some reported genotype-phenotype correlations . However, surveillance and prophylactic surgery should be tailored to the affected individual's phenotype and not based solely on genotype. Some studies report wide phenotypic variability in individuals with the same variant. Of individuals with phenotypic criteria of attenuated FAP, 78% had a pathogenic variant in one of three regions: the 5' end of APC (codon 1-233), the alternative spliced region of exon 9 (codon 311-412), or 3' of codon 1595. However, genotype does not always predict colorectal phenotype; of individuals with a pathogenic variant in one of these three regions typically associated with attenuated FAP, 65% had ≤100 colorectal adenomas and 35% had classic FAP and had undergone colectomy. The median age of colectomy was 18 years . Figure 1. Schematic representation of APC APC consists of 15 exons and 2843 codons. Most germline variants are located in the 5' half of APC, particularly in codons 1061 and 1309. Germline variants in the central part of the gene are often associated with classic FAP. Germline variants between codons 1250 and 1464 are associated with profuse polyposis, whereas variants in the 5' or 3' ends cause attenuated FAP. Table 3. Genotype-Phenotype Correlations in APC-Associated Conditions
Phenotype | Location/Type of APC Pathogenic Variant | Comments | Reference(s) |
|---|---|---|---|
FAP (classic form) | Whole-gene deletion | Attenuated FAP |
In FAP, the penetrance is 100%. In attenuated FAP, the penetrance of colonic polyposis is less well understood, although the estimate of CRC risk by age 80 years is approximately 70% . In GAPPS, the penetrance of FGPs and/or intestinal-type gastric adenocarcinoma is unknown.
Source: GeneReviews — "APC-Associated Polyposis Conditions"
The National Comprehensive Cancer Network (NCCN) has published an algorithm for consideration of the diagnosis of both familial adenomatous polyposis (FAP) and attenuated FAP (full text). These guidelines include recommendations for genetic testing of APC. Consensus guidelines specific for gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) are not yet available. According to the NCCN guidelines, an APC-associated polyposis condition should be suspected in individuals with any of the following clinical features:
Source: GeneReviews — "APC-Associated Polyposis Conditions"
Hereditary Disorders to Consider in the Differential Diagnosis APC-associated polyposis conditions may be distinguished from other inherited colorectal cancer conditions and other gastrointestinal polyposis syndromes by molecular genetic testing, histopathologic findings, and phenotypic characteristics. Table 4. Selected Hereditary Polyposis and Colorectal Cancer Syndromes in the Differential Diagnosis of APC-Associated Polyposis Conditions
Gene(s) / Genetic Mechanism | Disorder | MOI | Comment |
|---|---|---|---|
15q15.3q22.1 duplication1BMPR1ASMAD4 | Hereditary mixed polyposis syndrome (HMPS) (OMIM 601228) | AD | Assoc w/ risk for CRC multiple different types of colorectal polyps. Characteristic lesions are mixed juvenile-adenomatous colon polyps. Adenomas, hyperplastic serrated adenomas, mixed hyperplastic-adenomatous polyps may also occur. |
Genetic testing for APC is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for gastric adenocarcinoma and proximal polyposis of the stomach has been reported in the published literature.
No approved treatments are currently available for gastric adenocarcinoma and proximal polyposis of the stomach. The disease remains an area of unmet medical need.
Individuals who are diagnosed with classic familial adenomatous polyposis (FAP) or attenuated FAP should be counseled about age-appropriate recommendations for and , in addition to , as outlined in this section. Currently, consensus management guidelines for gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) are unavailable.
Practice parameters, including information on surgery, have been outlined by the following professional groups:
National Comprehensive Cancer Network (NCCN) (full text)
American Society for Gastrointestinal Endoscopy (full text)
American College of Gastroenterology (full text)
American Society of Colon and Rectal Surgeons (full text)
American Society of Clinical Oncology (full text)
British Society of Gastroenterology (full text)
Society of Surgical Oncology (full text)
(full text)
European Society of Gastrointestinal Endoscopy (full text)
Source: GeneReviews — "APC-Associated Polyposis Conditions"
Surgery and desmoid risk. There is evidence that the risk of developing desmoid tumors is increased following abdominal surgery and may be higher following surgical procedures that require two stages. Individuals at high risk for desmoids (e.g., women, those with APC pathogenic variants in codons 1395-1493, those with a family history of desmoids) should consider an operation that is likely to be a single stage to minimize the need for a second surgery. Surgery and fecundity. There is the likelihood of a lower rate of fecundity in women after a total colectomy with IPAA . Although most of the concern is related to results from surgeries performed for inflammatory bowel disease, this issue should be included as part of the discussion of surgical options with women with FAP .
Source: GeneReviews — "APC-Associated Polyposis Conditions"
In a single controlled trial, the omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) led to a 20%-30% decrease in FAP polyp size and number . A Phase III multicenter trial studying the effect of EPA on rectal polyp burden after total colectomy with IRA is currently under way (NCT03806426). There are also currently several multicenter trials on obeticholic acid, lorpucitinib (pan-janus kinase inhibitor), encapsulated sirolimus, and guselkumab (IL-23 inhibitor). Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions.
Source: GeneReviews — "APC-Associated Polyposis Conditions"
View trials for gastric adenocarcinoma and proximal polyposis of the stomach
Multiple professional societies have published guidelines based on the available evidence to date as well as expert consensus . The following surveillance recommendations are based on these expert society guidelines. Table 6. Recommended Surveillance for Individuals with FAP
System/Concern | Evaluation | Frequency/Comment |
|---|---|---|
polyps | Colonoscopy | Every 1-2 yrs beginning: at age 10-15 yrs for classic FAP; in late adolescence for attenuated FAP In persons who have undergone subtotal colectomy w/ileorectal anastomosis: surveillance of remaining rectum |
polyps cancer | EGD w/complete visualization of ampulla of Vater (using duodenoscope or clear cap) | Every 6 mos-5 yrs depending on duodenal adenoma burden2 beginning at age 20-25 yrs or prior to colectomy Consider complete small bowel visualization by video capsule endoscopy or CT/MR enterography esp if duodenal polyposis is advanced (based on Spigelman scoring system). |
CNS tumors | Neurologic exam | Annually beginning at diagnosis Hepatoblastoma |
cancer | EGD | Every 6 mos-5 yrs (w/duodenal exam), beginning at age 20-25 yrs; If polyps are neoplastic or large consider annual exams. Non-malignant extraintestinal manifestations |
Source: GeneReviews — "APC-Associated Polyposis Conditions"
Phenotype severity distribution: 1 always present feature, 2 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for gastric adenocarcinoma and proximal polyposis of the stomach.
32 publications have been identified in PubMed for gastric adenocarcinoma and proximal polyposis of the stomach. Research spans Review / Meta-Analysis (41%), Case Report / Case Series (34%), and Epidemiology / Natural History (19%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 13 | 41% |
Patient case studies | 11 | 34% |
Disease patterns and progression | 6 | 19% |
Testing and diagnosis research | 1 | 3% |
Laboratory research | 1 | 3% |
Perati SR (2026). [PMID: 41087777](https://pubmed.ncbi.nlm.nih.gov/41087777/). *Ann Surg Oncol*. [Review / Meta-Analysis]
Park JS (2026). [PMID: 41822757](https://pubmed.ncbi.nlm.nih.gov/41822757/). *Front Genet*. [Case Report / Case Series]
Pesic I (2026). [PMID: 42200866](https://pubmed.ncbi.nlm.nih.gov/42200866/). *Reports (MDPI)*. [Case Report / Case Series]
Woo SWD (2026). [PMID: 41838833](https://pubmed.ncbi.nlm.nih.gov/41838833/). *Digestion*. [Review / Meta-Analysis]
Skat-Rørdam PA (2026). [PMID: 41523585](https://pubmed.ncbi.nlm.nih.gov/41523585/). *Case Rep Genet*. [Case Report / Case Series]
Rogalidou M (2026). [PMID: 41736231](https://pubmed.ncbi.nlm.nih.gov/41736231/). *Clin Exp Pediatr*. [Review / Meta-Analysis]
Maratt JK (2026). [PMID: 41504306](https://pubmed.ncbi.nlm.nih.gov/41504306/). *Am J Gastroenterol*. [Review / Meta-Analysis]
Perati SR (2026). [PMID: 41162747](https://pubmed.ncbi.nlm.nih.gov/41162747/). *Ann Surg Oncol*. [Review / Meta-Analysis]
Kotani S (2026). [PMID: 40728066](https://pubmed.ncbi.nlm.nih.gov/40728066/). *Histol Histopathol*. [Review / Meta-Analysis]
Yang CH (2026). [PMID: 41694105](https://pubmed.ncbi.nlm.nih.gov/41694105/). *Exp Ther Med*. [Case Report / Case Series]
Data assembled from 8 of 12 sources · Last updated Sep 19, 2026, 2:45 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Exon 9 (codons 311-412) | Extraintestinal manifestations (e.g., CHRPE, desmoid tumors) are rare. | , | — |
GAPPS | APC promoter 1B | — | — |
Somatic mosaicism | Codons 1286-1513 (most common) | Colon phenotype:; 65% attenuated FAP; 30% FAP; 5% no adenomas | , , |
Brain tumors | Codons 697-1224 | 3x risk brain tumor; 13x risk medulloblastoma | — |
CHRPE | Codons 148-2043 | Codons 311-1444 | See footnote 2. Whole-gene deletion |
Desmoids | Codons 1395-1493 | Odds ratio: 4.37 | — |
5' of codon 400 | Incidence: 14.9% | Codons 401-1400 | Incidence: 23.3% 3' of codon 1400 |
Duodenal adenomas | Codons 976-1067 | 4x risk | — |
Epidermoid cysts | Codons 457-1493 | — | — |
Osteomas | Codons 767-1578 | — | — |
Profuse polyposis | Codons 1250-1464 | Average of 5,000 polyps | — |
Thyroid cancer | 5' end (codon 1061 or proximal to codon 938) | CHRPE = congenital hypertrophy of the retinal pigment epithelium; FAP = familial adenomatous polyposis; GAPPS = gastric adenocarcinoma and proximal polyposis of the stomach 1. Variants 5' of codon 233 are the most commonly described variants associated with attenuated FAP . 2. | — |
Source: GeneReviews — "APC-Associated Polyposis Conditions"
AXIN2 | AXIN2-assoc polyposis (oligodontia-CRC syndrome) (OMIM 608615) | AD | Ectodermal dysplasia BMPR1A |
SMAD4 | Juvenile polyposis syndrome (JPS) | AD | Characterized by predisposition for hamartomatous polyps, which is often the distinguishing feature between FAP JPS. Hamartomatous polyps occur in the GI tract – specifically stomach, small intestine, colon, rectum. Most persons w/JPS have some polyps by age 20 yrs. |
PMS2 | Lynch syndrome (hereditary non-polyposis colon cancer) | AD | It may be difficult to distinguish Lynch syndrome from attenuated FAP in persons w/early-onset CRC few adenomatous colonic polyps. Family history of extracolonic cancers manifestations, MSI testing, /or IHC testing on tumor tissue may be helpful in distinguishing the 2 disorders. MLH1 MSH2 MSH6 |
PMS2 | Constitutional mismatch repair deficiency (CMMRD) (See Lynch syndrome.) | AR | Affected persons frequently have brain tumors, hematologic malignancies, CRC, /or other Lynch syndrome cancers in childhood. Caf au lait macules /or axillary/inguinal freckling are seen in most persons; multiple colorectal adenomas mimicking attenuated FAP may also be present. |
MSH3 | MSH3-assoc polyposis (OMIM 617100) | AR | Colorectal duodenal adenomas, CRC, gastric cancer, early-onset astrocytoma |
MUTYH | MUTYH polyposis (MAP) | AR | Assoc w/predisposition to multiple adenomas or polyposis coli. The colonic phenotype of MAP can be similar to attenuated FAP. If an APC pathogenic variant is not identified in a person w/colonic polyposis, molecular genetic testing of MUTYH should be considered. |
NF1 | Neurofibromatosis type 1 (NF1) | AD | Persons w/NF1 may exhibit multiple intestinal polypoid neurofibromas or ganglioneuromas in small bowel, stomach, colon. |
NTHL1 | NTHL1 tumor syndrome (NTHL1-assoc polyposis) | AR | Characterized by lifetime risk for CRC, breast cancer, colorectal polyposis. |
Source: GeneReviews — "APC-Associated Polyposis Conditions"